Driving Clinical Activity of TCR-T Cells in the Challenging Solid Tumour Setting

Time: 11:00 am
day: Day 1 – Track B – Morning


  • Developing TCR-engineered T-cells against PRAMEpositive solid tumours
  • Leveraging the power of TCR-T cells: safety and antitumour activity of TCR-T cells directed against PRAMEpositive solid tumours
  • Potentiating anti-tumour activity through CD8αβ cotransduction
  • Tackling the tumour microenvironment by next generation TCR-T cells directed against a novel tumour stroma target